A global, regional, and national survey on burden and Quality of Care Index (QCI) of hematologic malignancies; global burden of disease systematic analysis 1990–2017

• Published in: Experimental Hematology & Oncology
• Main Authors: Keykhaei, Mohammad, Masinaei, Masood, Mohammadi, Esmaeil, Azadnajafabad, Sina, Rezaei, Negar, Saeedi Moghaddam, Sahar, Rezaei, Nazila, Nasserinejad, Maryam, Abbasi-Kangevari, Mohsen, Malekpour, Mohammad-Reza, Ghamari, Seyyed-Hadi, Haghshenas, Rosa, Koliji, Kamyar, Kompani, Farzad, Farzadfar, Farshad
• Format: Article in Journal/Newspaper
• Language: English
• Published: Springer Science and Business Media LLC 2021
• Subjects: Cancer Research; Oncology; Hematology; New Zealand; Iceland
• Online Access: http://dx.doi.org/10.1186/s40164-021-00198-2; http://link.springer.com/content/pdf/10.1186/s40164-021-00198-2.pdf; http://link.springer.com/article/10.1186/s40164-021-00198-2/fulltext.html

Abstract Background Hematologic malignancies (HMs) are a heterogeneous group of cancers that comprise diverse subgroups of neoplasms. So far, despite the major epidemiologic concerns about the quality of care, limited data are available for patients with HMs. Thus, we created a novel measure—Quality of Care Index (QCI)—to appraise the quality of care in different populations. Methods The Global Burden of Disease data from 1990 to 2017 applied in our study. We performed a principal component analysis on several secondary indices from the major primary indices, including incidence, prevalence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years (DALYs) to create the QCI, which provides an overall score of 0–100 of the quality of cancer care. We estimated the QCI for each age group on different scales and constructed the gender disparity ratio to evaluate the gender disparity of care in HMs. Results Globally, while the overall age-standardized incidence rate of HMs increased from 1990 to 2017, the age-standardized DALYs and death rates decreased during the same period. Across countries, in 2017, Iceland (100), New Zealand (100), Australia (99.9), and China (99.3) had the highest QCI scores for non-Hodgkin lymphoma, multiple myeloma, Hodgkin lymphoma, and leukemia. Conversely, Central African Republic (11.5 and 6.1), Eritrea (9.6), and Mongolia (5.4) had the lowest QCI scores for the mentioned malignancies respectively. Overall, the QCI score was positively associated with higher sociodemographic of nations, and was negatively associated with age advancing. Conclusions The QCI provides a robust metric to evaluate the quality of care that empowers policymakers on their responsibility to allocate the resources effectively. We found that there is an association between development status and QCI and gender equity, indicating that instant policy attention is demanded to improve health-care access.